gms | German Medical Science

27. Deutscher Krebskongress

Deutsche Krebsgesellschaft e. V.

22. - 26.03.2006, Berlin

The results of a prospective study from expression of VEGF, VEGF-C, VEGF-D in patients with ovarian cancer

Meeting Abstract

  • corresponding author presenting/speaker Natalja Sentschuk- Schmidt - Universitätsmedizin Berlin Charité Klinik für Frauenheilkunde Campus Virchow, Blumberg, Deutschland
  • Alexander Mustea - Universitätsmedizin Berlin Charité Klinik für Frauenheilkunde Campus Virchow
  • Dominique Koensgen - Universitätsmedizin Berlin Charité Klinik für Frauenheilkunde Campus Virchow
  • Jalid Sehouli - Universitätsmedizin Berlin Charité Klinik für Frauenheilkunde Campus Virchow
  • Werner Lichtenegger - Universitätsmedizin Berlin Charité Klinik für Frauenheilkunde Campus Virchow

27. Deutscher Krebskongress. Berlin, 22.-26.03.2006. Düsseldorf, Köln: German Medical Science; 2006. DocPO366

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter: http://www.egms.de/de/meetings/dkk2006/06dkk476.shtml

Veröffentlicht: 20. März 2006

© 2006 Sentschuk- Schmidt et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielf&aauml;ltigt, verbreitet und &oauml;ffentlich zug&aauml;nglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

Introduction: VEGF is the most potent factors in angiogenesis and is involved in tumorgenesis of various solid tumors. There is no valid data for ovarian cancer.

Methods: From October 2002 till October 2004 in the study were prospectivly enrolled 54 patients with ovarian cancer (28 primary; 28 recurrence) (OC) and 25 woman with no history of cancer (control group) (CG). VEGF and VEGF D were analysed in serum and ascites with the Enzym Limked Immunosorbet Assay (ELISA). VEGF C were analysed in the tissue with the Light Cycler PCR. SPSS 11.5 software was used for statistical analysis.

Results: There was a significant difference in VEGF concentration between patients with OC (2635,35 pg/ml) and the control group (208.75 pg/ml) (p< 0,005). The significant differences was also observed in expression of VEGF in patients with primary ovarian carcinoma an the CG (p= 0,003). There was a significant correlation between the concentration of VEGF in ascites and serum in connection with a peritoneal carcinomatosis (p= 0,036/0,029). The ascites expression of VEGF- D in patients with recurrence OC significant correlatet with spleen and diaphragm metastasis (p= 0,024/0,05). The hight concentration of VEGF- C were find in OC group ( p< 0,05) and in patients with ovarian cancer and with ascites (p=0,016).

Conclusions: VEGF is over expressed in ovarian cancer group, especially in patients with peritoneal carcinomatosis. The members of VEGF family seems to be possible targets for anti-angiogenic therapy of ovarian cancer.